Hologic Inc. is a global medical technology company focused on improving women's health through the development and delivery of innovative products and solutions. The company specializes in diagnostic, surgical, and medical imaging systems, with a particular emphasis on breast health, cervical health, and skeletal health. Hologic's offerings include advanced molecular diagnostics, imaging systems for breast cancer detection, and various surgical instruments and techniques that enhance patient care. With a commitment to advancing health outcomes for women, Hologic actively invests in research and development to address unmet medical needs and improve access to vital healthcare solutions. Read More
Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Panther Fusion® Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays. The company also announced that the assays obtained CE marking in the European Union in accordance with In Vitro Diagnostic Regulation (IVDR). These highly sensitive molecular tests are designed to rapidly detect the most common bacterial pathogens responsible for infectious gastroenteritis.
Global women’s health leader Hologic, Inc. (Nasdaq: HOLX) will mark the start of Breast Cancer Awareness Month by ringing the Nasdaq opening bell for the 19th year. The company will also continue its comprehensive #BustTheMyth patient education campaign following new survey data that shows nearly half of women who are recommended a mammogram either skip or delay the exam.
VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it has entered into a co-marketing and services agreement with Hologic Diagenode, part of Hologic Inc. (NASDAQ: HOLX), to promote Volition’s Nu.Q® Discover service. The program offers drug developers and scientists a suite of assays for rapid epigenetic profiling across disease model development, preclinical testing, and clinical studies.
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the medical devices & supplies - imaging, diagnostics stocks, including Hologic (NASDAQ:HOLX) and its peers.
Data from two groundbreaking studies evaluating the performance of Hologic’s (Nasdaq: HOLX) artificial intelligence (AI)-powered mammography technology will be presented today at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting in Aberdeen, Scotland.
The healthcare sector stands on the precipice of a monumental transformation, driven by the relentless advance of Artificial Intelligence (AI). From streamlining administrative tasks to enhancing diagnostic accuracy, AI promises a future of more efficient, accessible, and personalized care. However, this technological revolution is not without its complexities, sparking debates
Wall Street kept driving equity valuations higher on Friday, extending the momentum from Thursday when all major U.S. benchmarks closed at record highs following the Federal Reserve's rate cut.
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Thursday to find the gap up and gap down stocks in today's session.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently -
over the past six months, the collective 1.4% gain for healthcare stocks has fallen short of the S&P 500’s 15.5% rise.
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations.
However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 23rd Annual Morgan Stanley Global Healthcare Conference in New York at 10:45 a.m. Eastern Time on Tuesday, September 9th.
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities.
However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
Wall Street has issued downbeat forecasts for the stocks in this article.
These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
Hologic (HOLX) shows strong technicals with an 8 rating and a high-grade bull flag setup rated 9, signaling a potential breakout above $68.77 resistance.
Hologic delivered a solid second quarter, surpassing Wall Street’s expectations for both revenue and non-GAAP earnings. Management attributed this outperformance to improved commercial execution in the Breast Health segment, particularly in imaging and interventional sales, as well as ongoing progress in diagnostics and surgical divisions. CEO Stephen MacMillan emphasized that “the operative word for Hologic in the third quarter was progress,” pointing to a rebound in previously challenged business areas and the successful integration of recent acquisitions, such as Endomag. The company also highlighted operational discipline, including expense control and tariff mitigation, as contributors to the positive results.
Medical technology company Hologic (NASDAQ:HOLX) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 1.2% year on year to $1.02 billion. The company expects next quarter’s revenue to be around $1.04 billion, close to analysts’ estimates. Its non-GAAP profit of $1.08 per share was 2.7% above analysts’ consensus estimates.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Hologic Inc (HOLX) presents a strong value investment opportunity with solid valuation, profitability, and financial health, aligning with Benjamin Graham's principles. Undervalued with strong fundamentals.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH)
will be reporting earnings this Wednesday before market hours. Here’s what investors should know.
